Icon Plc $ICLR Shares Sold by Fayez Sarofim & Co

Key Points

• Fayez Sarofim & Co. trimmed its stake in Icon by 29.6% in Q3, selling 27,920 shares and now holds 66,433 shares worth about $11.63 million (≈0.08% of the company).
• Massachusetts Financial Services increased its position to 3,752,008 shares (≈$545.73 million), and institutional investors now own 95.61% of Icon's stock.
• Wall Street's consensus is a Hold with an average price target of $146.80 (6 Buy / 9 Hold / 2 Sell); Icon recently traded near $98.33 with a one‑year range of $66.57–$211 and a $7.94B market cap.

Fayez Sarofim & Co lessened its holdings in Icon Plc (NASDAQ:ICLR - Free Report) by 29.6% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 66,433 shares of the medical research company's stock after selling 27,920 shares during the period. Fayez Sarofim & Co owned approximately 0.08% of Icon worth $11,626,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Allworth Financial LP raised its stake in shares of Icon by 64.4% in the second quarter. Allworth Financial LP now owns 1,396 shares of the medical research company's stock valued at $203,000 after acquiring an additional 547 shares in the last quarter. Geode Capital Management LLC grew its stake in Icon by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 84,370 shares of the medical research company's stock worth $12,272,000 after purchasing an additional 2,159 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Icon by 21.0% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,752,008 shares of the medical research company's stock worth $545,730,000 after purchasing an additional 650,379 shares during the period. SG Americas Securities LLC increased its holdings in Icon by 12.3% during the 2nd quarter. SG Americas Securities LLC now owns 15,962 shares of the medical research company's stock worth $2,322,000 after purchasing an additional 1,743 shares during the period. Finally, Raiffeisen Bank International AG raised its position in Icon by 7.1% in the 2nd quarter. Raiffeisen Bank International AG now owns 7,500 shares of the medical research company's stock valued at $1,094,000 after purchasing an additional 500 shares in the last quarter. Hedge funds and other institutional investors own 95.61% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ICLR shares. Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the company a "neutral" rating in a research note on Tuesday, February 17th. Mizuho set a $216.00 target price on shares of Icon in a report on Friday, January 9th. Weiss Ratings reiterated a "hold (c)" rating on shares of Icon in a research note on Monday, December 29th. BMO Capital Markets reiterated a "market perform" rating and set a $100.00 price target on shares of Icon in a report on Thursday, February 12th. Finally, Bank of America reissued an "underperform" rating and issued a $75.00 price objective on shares of Icon in a research report on Thursday, February 12th. Six research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $146.80.

Icon Trading Up 0.9%

ICLR opened at $98.33 on Monday. Icon Plc has a one year low of $66.57 and a one year high of $211.00. The company has a market cap of $7.94 billion, a P/E ratio of 13.31, a PEG ratio of 2.52 and a beta of 1.36. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.06 and a current ratio of 1.06. The business's 50-day simple moving average is $144.09 and its 200-day simple moving average is $165.40.

Icon Profile

Icon plc NASDAQ: ICLR is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon's service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.